Summary - A new market study, titled “Global US Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Insights, Trends and Forecast (2020-2024) ” has been featured on WiseGuy Reports.

The U.S. OAB market is estimated to reach US$3.49 billion in 2031, growing at a CAGR of 5.01%, for the period spanning from 2021-2031. The factors such as rising ageing population, increasing healthcare expenditure, growing obese population, surging diabetic prevalence, increasing coffee consumption and accelerating economic growth are expected to drive the market growth. However, growth of the industry would be challenged by entry of generic drugs, stringent regulations, associated business risk and side effects of oral therapies. A few notable trends include advancing innovative therapies, rising awareness of overactive bladder, growing adoption of procedural (third line) therapy, development of gene therapy and progressing drug pipeline.
The three main treatment approaches for the treatment of overactive bladder are behavioural therapy (Bladder Training & Pelvic Floor Exercises), prescription therapy (Oral Anticholinergics & β3 Adrenoreceptor Agonist) and procedural therapy (BOTOX & Neuromodulation).
The fastest growing market is the U.S. owing to continuous advancement in β3 Adrenoreceptor Agonist drugs, increasing OAB population and growing research & development efforts by domestic pharmaceutical firms to launch novel drugs with innovative mechanism of actions drugs.
ALSO READ : https://www.medgadget.com/2020/09/us-overactive-bladder-market-2020...
Scope of the report:
• The report provides a comprehensive analysis of the U.S. OAB market, segmented on the basis of drug class i.e. Anticholinergics and β3 Adrenoreceptor Agonist and drug type i.e. Vibegron and Mirabegron.
• The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
• The competitive landscape of the market, along with the company profiles of leading players [Allergan Plc, Pfizer Inc., Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Medtronic Plc and Sumitomo Chemical Co., Ltd. (Urovant Sciences Ltd.)] are also presented in detail.
Key Target Audience:
• Drug Manufacturers
• Raw Material Suppliers
• End Users
• Consulting Firms
• Investment Banks
• Government Bodies & Regulating Authorities
FOR MORE DETAILS: https://www.wiseSummary - A new market study, titled “Global US Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Insights, Trends and Forecast (2020-2024) ” has been featured on WiseGuy Reports.

The U.S. OAB market is estimated to reach US$3.49 billion in 2031, growing at a CAGR of 5.01%, for the period spanning from 2021-2031. The factors such as rising ageing population, increasing healthcare expenditure, growing obese population, surging diabetic prevalence, increasing coffee consumption and accelerating economic growth are expected to drive the market growth. However, growth of the industry would be challenged by entry of generic drugs, stringent regulations, associated business risk and side effects of oral therapies. A few notable trends include advancing innovative therapies, rising awareness of overactive bladder, growing adoption of procedural (third line) therapy, development of gene therapy and progressing drug pipeline.
The three main treatment approaches for the treatment of overactive bladder are behavioural therapy (Bladder Training & Pelvic Floor Exercises), prescription therapy (Oral Anticholinergics & β3 Adrenoreceptor Agonist) and procedural therapy (BOTOX & Neuromodulation).
The fastest growing market is the U.S. owing to continuous advancement in β3 Adrenoreceptor Agonist drugs, increasing OAB population and growing research & development efforts by domestic pharmaceutical firms to launch novel drugs with innovative mechanism of actions drugs.
ALSO READ : https://www.medgadget.com/2020/09/us-overactive-bladder-market-2020...
Scope of the report:
• The report provides a comprehensive analysis of the U.S. OAB market, segmented on the basis of drug class i.e. Anticholinergics and β3 Adrenoreceptor Agonist and drug type i.e. Vibegron and Mirabegron.
• The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
• The competitive landscape of the market, along with the company profiles of leading players [Allergan Plc, Pfizer Inc., Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Medtronic Plc and Sumitomo Chemical Co., Ltd. (Urovant Sciences Ltd.)] are also presented in detail.
Key Target Audience:
• Drug Manufacturers
• Raw Material Suppliers
• End Users
• Consulting Firms
• Investment Banks
• Government Bodies & Regulating Authorities
FOR MORE DETAILS: https://www.wiseguyreports.com/reports/5266284-us-overactive-bladde...
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
sales@WiseGuy Reports.com
Ph: +162-825-80070 (US)
Ph: +44 203 500 2763 (UK)

guyreports.com/reports/5266284-us-overactive-bladder-anticholinergics-beta-adrenoreceptor-agonists-market
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
sales@WiseGuy Reports.com
Ph: +162-825-80070 (US)
Ph: +44 203 500 2763 (UK)